Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价LPM526000133富马酸盐胶囊(LY03017)在健康成年受试者中单次口服给药的安全性、耐受性及药代动力学的随机、双盲、安慰剂对照、剂量递增Ⅰ期临床研究
[Translation] A randomized, double-blind, placebo-controlled, dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of a single oral administration of LPM526000133 fumarate capsules (LY03017) in healthy adult subjects
主要目的:考察LY03017单次口服给药后在健康成年受试者中的安全性和耐受性。次要目的:考察LY03017单次口服给药后在健康成年受试者中的药代动力学(PK)特征。
[Translation] Primary objective: To investigate the safety and tolerability of LY03017 in healthy adult subjects after a single oral administration. Secondary objective: To investigate the pharmacokinetic (PK) characteristics of LY03017 in healthy adult subjects after a single oral administration.
评价LPM526000133富马酸盐胶囊(LY03017)在健康成年受试者中单次口服给药的安全性、耐受性及药代动力学的随机、双盲、安慰剂对照、剂量递增Ⅰ期临床研究
[Translation] A randomized, double-blind, placebo-controlled, dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of a single oral administration of LPM526000133 fumarate capsules (LY03017) in healthy adult subjects
主要目的:考察LY03017单次口服给药后在健康成年受试者中的安全性和耐受性。次要目的:考察LY03017单次口服给药后在健康成年受试者中的药代动力学(PK)特征。
[Translation] Primary objective: To investigate the safety and tolerability of LY03017 in healthy adult subjects after a single oral administration. Secondary objective: To investigate the pharmacokinetic (PK) characteristics of LY03017 in healthy adult subjects after a single oral administration.
评价LPM526000133富马酸盐胶囊(LY03017)在健康成年受试者中单次口服给药的安全性、耐受性及药代动力学的随机、双盲、安慰剂对照、剂量递增Ⅰ期临床研究
[Translation] A randomized, double-blind, placebo-controlled, dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of a single oral administration of LPM526000133 fumarate capsules (LY03017) in healthy adult subjects
主要目的:考察LY03017单次口服给药后在健康成年受试者中的安全性和耐受性。
次要目的:考察LY03017单次口服给药后在健康成年受试者中的药代动力学(PK)特征。
[Translation] Primary objective: To investigate the safety and tolerability of LY03017 in healthy adult subjects after a single oral administration.
Secondary objective: To investigate the pharmacokinetic (PK) characteristics of LY03017 in healthy adult subjects after a single oral administration.
100 Clinical Results associated with Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
100 Deals associated with Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.